Promising One-Year Results from CD19-Targeted CAR NK Therapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
<p>Researchers from <a href="http://www.MDAnderson.org">The University of Texas MD Anderson Cancer Center</a> reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived <a href="https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html">chimeric antigen receptor (CAR) natural killer (NK) cell therapy</a> targeting CD19. </p>
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.
The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.